Radium-223 mechanism of action: implications for use in treatment combinations

Article metrics

Abstract

The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that 223Ra preferentially incorporates into newly formed bone matrix within osteoblastic metastatic lesions. The emitted high-energy alpha particles induce DNA double-strand breaks that might be irreparable and lead to cell death in nearby exposed tumour cells, osteoblasts and osteoclasts. Consequently, tumour growth and abnormal bone formation are inhibited by these direct effects and by the disruption of positive-feedback loops between tumour cells and the bone microenvironment. 223Ra might also modulate immune responses within the bone. The clinical utility of 223Ra has encouraged the development of other anticancer targeted alpha therapies. A thorough understanding of the mechanism of action could inform the design of new combinatorial treatment strategies that might be more efficacious than monotherapy. On the basis of the current mechanistic knowledge and potential clinical benefits, combination therapies of 223Ra with microtubule-stabilizing cytotoxic drugs and agents targeting the androgen receptor axis, immune checkpoint receptors or DNA damage response proteins are being explored in patients with CRPC and metastatic bone disease.

Key points

  • Radium-223 (223Ra) deposited in the intralesional bone matrix emits high-energy alpha-particles that induce potentially cytotoxic DNA double-strand breaks in cells within a 100-µm distance while sparing surrounding normal tissue.

  • 223Ra acts via a multi-modal mechanism, killing both tumour cells and the effector cells of pathological bone metabolism, osteoblasts and osteoclasts; 223Ra might also promote local antitumour immune responses.

  • Understanding the mode of action of 223Ra and its interactions with those of other anticancer agents offers potential for new treatment combinations for bone-metastatic cancers.

  • Clinical trials are investigating 223Ra in combination with agents targeting the androgen receptor signalling axis, cell microtubules, the immune response and the DNA damage response.

  • Current combination studies are preliminary and further clinical testing will be required to demonstrate safety, efficacy and clinical benefit.

  • 223Ra treatment in patients with metastatic castration-resistant prostate cancer has led to the development of other targeted alpha therapies for the treatment of patients with different cancers that also have bone-predominant metastases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: 223Ra and prostate cancer bone metastases.
Fig. 2: Mechanism of action of anticancer agents in prostate cancer.

References

  1. 1.

    American Institute for Cancer Research. Prostate cancer statistics. World Cancer Research Fund https://www.wcrf.org/dietandcancer/cancer-trends/prostatecancer-statistics (2018).

  2. 2.

    Pernar, C. H., Ebot, E. M., Wilson, K. M. & Mucci, L. A. The epidemiology of prostate cancer. Cold Spring Harb. Perspect. Med. 8, a030361 (2018).

  3. 3.

    National Cancer Institute. SEER cancer statistics review 1975–2014. https://seer.cancer.gov/archive/csr/1975_2014/.

  4. 4.

    Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016. JAMA Oncol. 4, 1553–1568 (2018).

  5. 5.

    James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).

  6. 6.

    Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).

  7. 7.

    Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).

  8. 8.

    de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

  9. 9.

    Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

  10. 10.

    Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

  11. 11.

    Fizazi, K. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 15, 1147–1156 (2014).

  12. 12.

    de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

  13. 13.

    Logothetis, C. J. et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13, 1210–1217 (2012).

  14. 14.

    Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983–992 (2012).

  15. 15.

    Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

  16. 16.

    Ryan, C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16, 152–160 (2015).

  17. 17.

    US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm (2017).

  18. 18.

    Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

  19. 19.

    Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

  20. 20.

    Beer, T. M. et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology 82, 410–415 (2013).

  21. 21.

    US Food and Drug Adminstration. Xofigo (radium Ra 223 dichloride). Prescribing Information. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf (2013).

  22. 22.

    European Medicines Agency. Xofigo: summary of product characteristics. EMA https://www.ema.europa.eu/documents/referral/xofigo-article-20-procedureannex-i-ii-iii_en.pdf (2018).

  23. 23.

    Henriksen, G., Breistol, K., Bruland, O. S., Fodstad, O. & Larsen, R. H. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62, 3120–3125 (2002).

  24. 24.

    Suominen, M. I. et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin. Cancer Res. 23, 4335–4346 (2017).

  25. 25.

    Bruland, O. S., Nilsson, S., Fisher, D. R. & Larsen, R. H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12, 6250s–6257s (2006).

  26. 26.

    Sgouros, G. et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311–328 (2010).

  27. 27.

    Suominen, M. I. et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J. Natl. Cancer Inst. 105, 908–916 (2013).

  28. 28.

    Coleman, R. et al. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res. Treat. 145, 411–418 (2014).

  29. 29.

    Ueno, N. T. et al. Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis. J. Clin. Oncol. 36, 1065 (2018).

  30. 30.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02366130?term=radium-223&cond=Breast+Cancer&rank=4 (2019).

  31. 31.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02258451 (2019).

  32. 32.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02258464 (2019).

  33. 33.

    Suominen, M. I. et al. Abstract 5202: additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model. Cancer Res. 77, 5202 (2017).

  34. 34.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02928029 (2019).

  35. 35.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02406521 (2019).

  36. 36.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02283749 (2019).

  37. 37.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02390934 (2019).

  38. 38.

    Sartor, O. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 15, 738–746 (2014).

  39. 39.

    Vogelzang, N. J. et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin. Genitourin. Cancer 15, 42–58 (2017).

  40. 40.

    Nilsson, S. et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann. Oncol. 27, 868–874 (2016).

  41. 41.

    Sternberg, C. N. et al. A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 36, 5008 (2018).

  42. 42.

    European Medicines Agency. EMA restricts use of prostate cancer medicine Xofigo. EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Xofigo/human_referral_prac_000071.jsp&mid=WC0b01ac05805c516f (2018).

  43. 43.

    Smith, M. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 408–419 (2019).

  44. 44.

    National Comprehensive Cancer Network. NCCN guidelines. Prostate cancer version 1. NCCN https://www.nccn.org (2018).

  45. 45.

    American Urological Association. Castration-resistant prostate cancer. AUA https://www.auanet.org/guidelines/prostate-cancer-castration-resistant-guideline (2018).

  46. 46.

    European Association of Urology. Prostate cancer guidelines. EAU https://uroweb.org/guideline/prostate-cancer/#6 (2019).

  47. 47.

    Parker, C. C. et al. Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial. Eur. Urol. https://doi.org/10.1016/j.eururo.2017.06.021 (2017).

  48. 48.

    Dizdarevic, S. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur. J. Nucl. Med. Mol. Imaging 46, 1102–1110 (2019).

  49. 49.

    Body, J. J., Casimiro, S. & Costa, L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat. Rev. Urol. 12, 340–356 (2015).

  50. 50.

    Casimiro, S., Guise, T. A. & Chirgwin, J. The critical role of the bone microenvironment in cancer metastases. Mol. Cell Endocrinol. 310, 71–81 (2009).

  51. 51.

    Gdowski, A., Ranjan, A. & Vishwanatha, J. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J. Exp. Clin. Cancer Res. 36, 108 (2017).

  52. 52.

    Logothetis, C. J. & Lin, S. H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5, 21–28 (2005).

  53. 53.

    Ottewell, P. D. The role of osteoblasts in bone metastasis. J. Bone Oncol. 5, 124–127 (2016).

  54. 54.

    Hagberg Thulin, M. et al. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis. Mol. Cell Endocrinol. 422, 182–191 (2016).

  55. 55.

    Liu, Q., Jernigan, D., Zhang, Y. & Fatatis, A. Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis. Chin. J. Cancer 30, 612–619 (2011).

  56. 56.

    Kimura, Y., Matsugaki, A., Sekita, A. & Nakano, T. Alteration of osteoblast arrangement via direct attack by cancer cells: new insights into bone metastasis. Sci. Rep. 7, 44824 (2017).

  57. 57.

    Hagiwara, M., Delea, T. E., Saville, M. W. & Chung, K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 16, 23–27 (2013).

  58. 58.

    Oefelein, M. G., Ricchiuti, V., Conrad, W. & Resnick, M. I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168, 1005–1007 (2002).

  59. 59.

    Berish, R. B., Ali, A. N., Telmer, P. G., Ronald, J. A. & Leong, H. S. Translational models of prostate cancer bone metastasis. Nat. Rev. Urol. 15, 403–421 (2018).

  60. 60.

    Deshayes, E. et al. Radium 223 dichloride for prostate cancer treatment. Drug Des. Dev. Ther. 11, 2643–2651 (2017).

  61. 61.

    Ritter, M. A., Cleaver, J. E. & Tobias, C. A. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 266, 653–655 (1977).

  62. 62.

    Mantel, E. MIRD monograph: radiobiology and dosimetry for radiopharmaceutical therapy with alpha-particle emitters (ed. Sgouros, G.). J. Nucl. Med. Technol. 44, 216 (2016).

  63. 63.

    Ceder, J. & Elgqvist, J. Targeting prostate cancer stem cells with alpha-particle therapy. Front. Oncol. 6, 273 (2016).

  64. 64.

    Abou, D. S. et al. Whole-body and microenvironmental localization of radium-223 in naive and mouse models of prostate cancer metastasis. J. Natl. Cancer Inst. 108, djv380 (2016).

  65. 65.

    Hodge, J. W., Guha, C., Neefjes, J. & Gulley, J. L. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology 22, 1064–1070; discussion 1075, 1080–1, 1084 (2008).

  66. 66.

    Gameiro, S. R., Ardiani, A., Kwilas, A. & Hodge, J. W. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology 3, e28643 (2014).

  67. 67.

    Weiner, L. M. & Lotze, M. T. Tumor-cell death, autophagy, and immunity. N. Engl. J. Med. 366, 1156–1158 (2012).

  68. 68.

    Abe, T. et al. STING recognition of cytoplasmic DNA instigates cellular defense. Mol. Cell 50, 5–15 (2013).

  69. 69.

    Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).

  70. 70.

    Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).

  71. 71.

    Sgouros, G. & Hobbs, R. F. Dosimetry for radiopharmaceutical therapy. Semin. Nucl. Med. 44, 172–178 (2014).

  72. 72.

    Flux, G. D. Imaging and dosimetry for radium-223: the potential for personalized treatment. Br. J. Radiol. 90, 20160748 (2017).

  73. 73.

    Pacilio, M. et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Eur. J. Nucl. Med. Mol. Imaging 43, 21–33 (2016).

  74. 74.

    Akabani, G. & Zalutsky, M. R. Microdosimetry of astatine-211 using histological images: application to bone marrow. Radiat. Res. 148, 599–607 (1997).

  75. 75.

    Akabani, G., Kennel, S. J. & Zalutsky, M. R. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. J. Nucl. Med. 44, 792–805 (2003).

  76. 76.

    Chouin, N. et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results. Radiat. Res. 171, 664–673 (2009).

  77. 77.

    Coutinho, I., Day, T. K., Tilley, W. D. & Selth, L. A. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr. Relat. Cancer 23, T179–T197 (2016).

  78. 78.

    Crona, D. J., Milowsky, M. I. & Whang, Y. E. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin. Pharmacol. Ther. 98, 582–589 (2015).

  79. 79.

    Attard, G., Belldegrun, A. S. & de Bono, J. S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241–1246 (2005).

  80. 80.

    Schalken, J. & Fitzpatrick, J. M. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 117, 215–225 (2016).

  81. 81.

    Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

  82. 82.

    Parker, C., Gillessen, S., Heidenreich, A., Horwich, A. & Committee, E. G. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v69–v77 (2015).

  83. 83.

    James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

  84. 84.

    Morris, M. J. et al. Optimizing anticancer therapy in metastatic non-castrate prostate cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 36, 1521–1539 (2018).

  85. 85.

    Saad, F. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 17, 1306–1316 (2016).

  86. 86.

    Sartor, O. et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist 23, 193–202 (2018).

  87. 87.

    Harshman, L. C. et al. First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza). Ann. Oncol. 28, 870P (2017).

  88. 88.

    Shore, N. D. et al. eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin. Genitourin. Cancer 16, 149–154 (2018).

  89. 89.

    O’Sullivan, J. M. et al. The case against the European Medicines Agency’s change to the label for radium-223 for the treatment of metastatic castration-resistant prostate cancer. Eur. Urol. 75, e51–e52 (2019).

  90. 90.

    Ton, F. N., Gunawardene, S. C., Lee, H. & Neer, R. M. Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 20, 464–470 (2005).

  91. 91.

    Faruqi, S. et al. Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors. Neurosurgery 83, 314–322 (2018).

  92. 92.

    Zhang, J. et al. Differences in responses to X-ray exposure between osteoclast and osteoblast cells. J. Radiat. Res. 58, 791–802 (2017).

  93. 93.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02194842 (2018).

  94. 94.

    Martin, S. K., Kamelgarn, M. & Kyprianou, N. Cytoskeleton targeting value in prostate cancer treatment. Am. J. Clin. Exp. Urol. 2, 15–26 (2014).

  95. 95.

    Cheetham, P. & Petrylak, D. P. Tubulin-targeted agents including docetaxel and cabazitaxel. Cancer J. 19, 59–65 (2013).

  96. 96.

    Kraus, L. A. et al. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest. New Drugs 21, 259–268 (2003).

  97. 97.

    Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992–8002 (2010).

  98. 98.

    Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019–6029 (2011).

  99. 99.

    Seiwert, T. Y., Salama, J. K. & Vokes, E. E. The concurrent chemoradiation paradigm—general principles. Nat. Clin. Pract. Oncol. 4, 86–100 (2007).

  100. 100.

    Perrotti, M. et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol. Oncol. 26, 276–280 (2008).

  101. 101.

    Balcer-Kubiczek, E. K., Attarpour, M., Jiang, J., Kennedy, A. S. & Suntharalingam, M. Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy 52, 231–240 (2006).

  102. 102.

    Bentzen, S. M., Harari, P. M. & Bernier, J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat. Clin. Pract. Oncol. 4, 172–180 (2007).

  103. 103.

    Fizazi, K. et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 27, 2429–2435 (2009).

  104. 104.

    Morris, M. J. et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J. Clin. Oncol. 27, 2436–2442 (2009).

  105. 105.

    Tu, S. M. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357, 336–341 (2001).

  106. 106.

    Morris, M. J. et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur. J. Cancer 114, 107–116 (2019).

  107. 107.

    Morris, M. J. et al. Updated results: a phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castrationresistant prostate cancer and bone metastases. J. Clin. Oncol. 34(15S), 5075 (2016).

  108. 108.

    Morris, M. J. et al. Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): a phase I/IIa clinical trial. J. Clin. Oncol. 35, 154 (2017).

  109. 109.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03574571 (2019).

  110. 110.

    Malamas, A. S., Gameiro, S. R., Knudson, K. M. & Hodge, J. W. Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget 7, 86937–86947 (2016).

  111. 111.

    Geary, S. M., Lemke, C. D., Lubaroff, D. M. & Salem, A. K. Proposed mechanisms of action for prostate cancer vaccines. Nat. Rev. Urol. 10, 149–160 (2013).

  112. 112.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02463799 (2019).

  113. 113.

    Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

  114. 114.

    US Food and Drug Administration. TECENTRIQ (atezolizumab) prescribing information. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf (2016).

  115. 115.

    US Food and Drug Administration. KEYTRUDA (pembrolizumab) prescribing information. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf (2014).

  116. 116.

    Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

  117. 117.

    US Food and Drug Administration. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. FDA https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm (2017).

  118. 118.

    Abida, W. et al. Microsatellite instability in prostate cancer and response to immune checkpoint blockade. J. Clin. Oncol. 36, 5020 (2018).

  119. 119.

    De Bono, J. et al. KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 36, 5007 (2018).

  120. 120.

    Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).

  121. 121.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03093428 (2019).

  122. 122.

    O’Connor, M. J. Targeting the DNA damage response in cancer. Mol. Cell 60, 547–560 (2015).

  123. 123.

    Mateo, J. et al. DNA repair in prostate cancer: biology and clinical implications. Eur. Urol. 71, 417–425 (2017).

  124. 124.

    Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

  125. 125.

    Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016).

  126. 126.

    Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).

  127. 127.

    Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).

  128. 128.

    Lorusso, D. et al. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des. Dev. Ther. 12, 1501–1509 (2018).

  129. 129.

    AstraZeneca. Lynparza™ (olaparib) granted breakthrough therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer. AstraZeneca https://www.astrazeneca.com/media-centre/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html# (2016).

  130. 130.

    Ramos, J. D., Mostaghel, E. A., Pritchard, C. C. & Yu, E. Y. DNA repair pathway alterations in metastatic castration-resistant prostate cancer responders to radium-223. Clin. Genitourin. Cancer 16, 106–110 (2018).

  131. 131.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03076203 (2017).

  132. 132.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03317392 (2019).

  133. 133.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03188965 (2019).

  134. 134.

    Wengner, A. M. et al. ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy radium-223 dichloride in preclinical tumor models. Cancer Res. 77, 836 (2017).

  135. 135.

    Isaacsson Velho, P. et al. Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects. Eur. Urol. 76, 170–176 (2018).

  136. 136.

    Oyen, W. J. & de Bono, J. S. Targeted alpha-based treatment of metastatic castration-resistant prostate cancer patients: revolutionizing systemic radiotherapy? J. Nucl. Med. 57, 1838–1839 (2016).

  137. 137.

    Hagemann, U. B. et al. Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma. Oncotarget 8, 56311–56326 (2017).

  138. 138.

    Hagemann, U. B. et al. In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid leukemia. Mol. Cancer Ther. 15, 2422–2431 (2016).

  139. 139.

    Dahle, J. et al. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab. Eur. J. Nucl. Med. Mol. Imaging 37, 93–102 (2010).

  140. 140.

    Heyerdahl, H., Abbas, N., Brevik, E. M., Mollatt, C. & Dahle, J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLOS ONE 7, e42345 (2012).

  141. 141.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02581878 (2019).

  142. 142.

    Chang, S. S. Overview of prostate-specific membrane antigen Rev. Urol. 6 (S10), 13–18 (2004).

  143. 143.

    Hammer, S. et al. Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer. Proc. Am. Assoc. Cancer Res. 58, 5202 (2017).

  144. 144.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03724747 (2019).

  145. 145.

    Kratochwil, C. et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J. Nucl. Med. 58, 1624–1631 (2017).

  146. 146.

    Kratochwil, C. et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J. Nucl. Med. 59, 795–802 (2018).

  147. 147.

    Nonnekens, J. et al. (213)Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-strand breaks in prostate cancer xenografts. Cancer Biother. Radiopharm. 32, 67–73 (2017).

  148. 148.

    Sathekge, M. et al. (213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 44, 1099–1100 (2017).

  149. 149.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02043678 (2019).

  150. 150.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02225704 (2018).

  151. 151.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02814669 (2019).

Download references

Acknowledgements

The authors thank P. Hoban (Cancer Communications and Consultancy Ltd, Knutsford, UK) for providing writing assistance funded by Bayer.

Author information

M.J.M., E.C., J.L.G., D.I.Q. and A.S. researched data for the article. All authors made a substantial contribution to the discussion of its content. M.J.M., E.C. and A.S. wrote the manuscript. All authors were involved in reviewing and editing the manuscript, and providing their approval of the final version for submission.

Correspondence to Michael J. Morris.

Ethics declarations

Competing interests

M.J.M. declares participation as a compensated member of advisory boards for Advanced Accelerated Applications, an uncompensated member of advisory boards for Bayer, Endocyte and Progenics and research funding (for institute) from Bayer, Endocyte, Progenics and Corcept. E.C. and T.A.G. declare participation as compensated members of a round-table meeting from Bayer and research funding (for institute) from Bayer. W.K.K. declares clinical trial support from Bayer. D.I.Q. declares participation as a compensated member of advisory boards from Astellas, Bayer, Janssen, Genzyme, Dendreon and AstraZeneca. A.S. is a full-time employee of Bayer. G.S. is a consultant for Bayer and holds ownership in a start-up company that Bayer has used for imaging and dosimetry analyses. J.L.G declares no competing interests.

Additional information

Peer review information

Nature Reviews Urology thanks S. Nilsson, J. O’Sullivan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morris, M.J., Corey, E., Guise, T.A. et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol 16, 745–756 (2019) doi:10.1038/s41585-019-0251-x

Download citation